Vnitr Lek 2020, 66(5):287-300 | DOI: 10.36290/vnl.2020.084
Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis
- 1 II. interní gastroenterologická klinika LF UK a FN Hradec Králové
- 2 Katedra interních oborů LF OU Ostrava
Cholestasis is defined as hepatocyte and cholangiocyte bile excretion failure or failure of bile transport to the duodenum. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis as chronic progressive cholestatic diseases are the common reasons of chronic cholestasis. Altogether with cholestatic laboratory picture the pruritus, liver osteodystrophy and fatigue are associated symptoms in both diseases. All associated symptoms and complications are needed to be diagnosed and treated early. In case of liver cirrhosis complicatons of accompanied portal hypertension should be treated and liver transplantation must be considered in all those patients. Diagnosis of PBC is based on cholestatic laboratory features, animitochondrial antibody positivity or typical histological patern. Most patients are asymptomatic in time of diagnosis. First line therapy is ursodeoxycholic acid. In case of first line therapy failure, the prognosis is unfavourable. In this case, second line therapy must be considered. In case of PSC the diagnosis is based on MRCP finding mainly, laboratory test and liver biopsy in some cases. Progressive inflamatory and fibrosing impairment affecting intrahepatic and extrahepatict biliary ducts and strong association with inflamatory bowel disease, especially ulcerative colitis is typical for PSC. Endoscopic therapy with dilatation of dominant structure is crucial. The effect of pharmacotherapy is still being discussed and ursodeoxycholic acid could be used. During follow up patients are in the risk of bacterial cholangitis and malignant tumor development (cholangiogenic and colorectal carcinoma mainly). In PSC patients the severe pruritus and reccurent bacterial cholangitis could be an indication for the liver transplantation.
Keywords: biliary cholangitis, diagnostics, cholangitis, cholestasis, sclerosing cholangitis, treatment.
Published: August 1, 2020 Show citation
References
- Jirsa M, Mareček P, Vítek L. Cholestáza. In: Hůlek P, Urbánek P (eds.) Hepatologie. 3 vydání. Praha: Grada 2018, 166-178.
- Hirschfield GM, Beuers U, Corpechot C, et al. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; pii: S0168-8278(17)30186-1.
Go to original source...
Go to PubMed...
- Fejfar T, Vaňásek T, Hůlek P, et al. Primární biliární cholangitida - doporučený postup České hepatologické společnosti ČLS JEP pro diagnostiku a léčbu. Gastroenterol Hepatol 2018; 72: 109-118.
Go to original source...
- A Name Change for PBC: Cholangitis replacing Cirrhosis, AASLD (online). (Cit. 20. 3. 2018). Dostupné z: http://www.aasld.org/name‑change‑pbc‑cholangitis‑replacing‑cirrhosis#sthash. hrd6kN6F.dpuf
- Invernizzi P, Lleo A, Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 2007; 27: 161-172.
Go to original source...
Go to PubMed...
- Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-683.
Go to original source...
Go to PubMed...
- Dahlqvist G, Gaouar F, Carrat F, et al. Large‑scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 2017; 65: 152-163.
Go to original source...
Go to PubMed...
- Hirschfield GM, Heathcote EJ. Antimitochondrial antibody‑negative primary biliary cirrhosis. Clin Liver Dis 2008; 12: 323-331.
Go to original source...
Go to PubMed...
- Kakuda Y, Harada K, Sawada‑Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol 2013; 44: 1107-1117.
Go to original source...
Go to PubMed...
- Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid. Gastroenterology 2013; 144: 560-569.
Go to original source...
Go to PubMed...
- Mayo PBC model (online). (Cit.28. 10. 2018). Dostupné z: https://www.mayoclinic.org/medical‑professionals/model‑end‑stage‑liver‑disease/updated‑natural‑history‑model‑for‑primary‑biliary‑cirrhosis
- Angulo P, Lindor KD, Therneau TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999; 19: 115-121.
Go to original source...
Go to PubMed...
- Parés A, Caballería L, Rodés J. Excellent long‑term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715-720.
Go to original source...
Go to PubMed...
- Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long‑term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-877.
Go to original source...
Go to PubMed...
- Kuiper EM, Hansen BE, de Vries RA, et al. Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-1287.
Go to original source...
Go to PubMed...
- Kumagi T, Guindi M, Fischer S, at al. Baseline Ductopenia and Treatment Response Predict Long‑Term Histological Progression in Primary Biliary Cirrhosis. Am J Gastroenterol 2010; 105: 2186-2194.
Go to original source...
Go to PubMed...
- Lammert C, Juran BD, Schlicht E, et al. Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients.J Gastroenterol 2014; 49: 1414-1420.
Go to original source...
Go to PubMed...
- Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long‑term outcome. J Hepatol 2011; 55: 1361-1367.
Go to original source...
Go to PubMed...
- Azemoto N, Abe M, Murata Y, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol 2009; 44: 630-634.
Go to original source...
Go to PubMed...
- Azemoto N, Kumagi T, Abe M, et al. Biochemical response to ursodeoxycholic acid predicts long‑term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res 2011; 41: 310-317.
Go to original source...
Go to PubMed...
- Momah N, Silveira MG, Jorgensen R, et al. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int 2012; 32: 790-795.
Go to original source...
Go to PubMed...
- Carbone M, Sharp SJ, Flack S, et al. The UKPBC risk scores: Derivation and validation of a scoring system for long‑term prediction of end‑stage liver disease in primary biliary cirrhosis. Hepatology 2016; 63: 930-950.
Go to original source...
Go to PubMed...
- Lammers WJ, Hirschfield GM, Corpechot C. Global PBC Study Group. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015; 149: 1804-1812. GLOBE kalkulátor http://www.globalpbc.com/globe
Go to original source...
Go to PubMed...
- Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double‑blind trial. Gastroenterology 1989; 97: 1268-1274.
Go to original source...
Go to PubMed...
- Juřica J. Ursodeoxycholová kyselina. Remedia 2016; 26: 529-535.
- Corpechot C, Carrat F, Bonnand AM, at al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196-1199.
Go to original source...
Go to PubMed...
- Poupon RE, Lindor KD, Cauch‑Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-890.
Go to original source...
Go to PubMed...
- Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-1290.
Go to original source...
Go to PubMed...
- Shi J, Wu C, Lin Y, et al. Long‑term effects of mid‑dose ursodeoxycholic acid in primary biliary cirrhosis: a meta‑analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 1529-1538.
Go to original source...
Go to PubMed...
- Lammers WJ, van Buuren HR, Hirschfield, et al. Levels of alkaline phosphate and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow up study. Gastroenterology 2014; 147: 1338-1349.
Go to original source...
Go to PubMed...
- Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid‑adverse effects and drug interactions. Aliment Pharmacol Ther 2003; 18: 963-972.
Go to original source...
Go to PubMed...
- EASL‑ALEH Clinical Practice Guidelines: Non‑invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264.Další literatura u autoraa na www.casopisvnitrnilekarstvi.cz
Go to original source...
Go to PubMed...
- Poupon RE, Lindor KD, Cauch‑Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113: 884-890.
Go to original source...
Go to PubMed...
- Nevens F, Andreone P, Mazzella G, et al. POISE Study Group. A Placebo‑Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016; 375: 631-643.
Go to original source...
Go to PubMed...
- Kowdley KV, Luketic V, Chapman R, et al. Obeticholic Acid PBC Monotherapy Study Group. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 2017; Ahead of print
Go to original source...
Go to PubMed...
- Samur S, Klebanoff M, Banken R, et al. Long‑term clinical impact and cost‑effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology 2017; 65: 920-928.
Go to original source...
Go to PubMed...
- Kanda T, Yokosuka O, Imazeki F, et al. Bezafibrate treatment: a newmedical approach for PBC patients? J Gastroenterol 2003; 38: 573-578.
Go to original source...
Go to PubMed...
- Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long‑term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 2015; 110: 423-431.
Go to original source...
Go to PubMed...
- Grigorian AY, Mardini HE, Corpechot C, et al. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta‑analysis. Clin Res Hepatol Gastroenterol 2015; 39: 296-306.
Go to original source...
Go to PubMed...
- Corpechot C, Chazouillères O, Rousseau A, et al. A Placebo‑Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 378: 2171-2181.
Go to original source...
Go to PubMed...
- Arenas F, Hervias I, Uriz M, et al. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest 2008; 118: 695-709.
Go to original source...
Go to PubMed...
- Leuschner M, Maier KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double‑blind trial. Gastroenterology 1999; 117: 918-925.
Go to original source...
Go to PubMed...
- Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three‑year randomized trial. Hepatology 2005; 41: 747-752.
Go to original source...
Go to PubMed...
- Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: primary sclerosing cholangitis. The American journal of gastroenterology 2015; 110: 646-659.
Go to original source...
Go to PubMed...
- European Society of Gastrointestinal Endoscopy; European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol 2017; 66: 1265-1281.
Go to PubMed...
- Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. Journal of hepatology 2012; 56: 1181-1188.
Go to original source...
Go to PubMed...
- Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis:natural history, prognostic factors and survival analysis. Hepatology (Baltimore, Md) 1989; 10: 430-436.
Go to original source...
Go to PubMed...
- Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364-1369.
Go to original source...
Go to PubMed...
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
Go to original source...
Go to PubMed...
- Hov J, Karlsen T. The microbiome in primary sclerosing cholangitis: current evidence and potential concepts. Semin Liver Dis 2017; 37: 314-331.
Go to original source...
Go to PubMed...
- Trivedi PJ, Adams DH. Mucosal immunity in liver autoimunity: a comprehensive review. J Autoimmun 2013; 46: 97-111.
Go to original source...
Go to PubMed...
- Dyson JK, Beuers U, Jones DJ, et al. Primary sclerosing cholangitis. Lancet 2018; 391: 2547-2559.
Go to original source...
Go to PubMed...
- Sebode M, Weiler‑Normann C, Liwinski T et al. Autoantibodies in Autoimmune Liver Disease - Clinical and Diagnostic Relevance. Front Immunol 2018; 9: 609.
Go to original source...
Go to PubMed...
- Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-2075.
Go to original source...
Go to PubMed...
- Ohara H, Nakazawa T, Kawa S, et al. Establishment of a serum IgG4 cut‑off value for the differential diagnosis of IgG4-related sclerosing cholangitis: a Japanese cohort. J Gastroenterol Hepatol 2013; 28: 1247-1251.
Go to original source...
Go to PubMed...
- Boonstra K, Culver EL, de Buy Wenniger LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology 2014; 59: 1954-1963.
Go to original source...
Go to PubMed...
- Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-715.
Go to original source...
Go to PubMed...
- Jendrek ST, Gotthardt D, Nitzsche T, et al. Anti‑GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut 2017; 66: 137-144.
Go to original source...
Go to PubMed...
- Weismuller TJ, Bergquist A, Imam M, et al. Patient age, sex and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017; 152: 1975-1984.
Go to original source...
Go to PubMed...
- Bjornsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002; 51: 731-735.
Go to original source...
Go to PubMed...
- Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small‑duct primary sclerosing cholangitis. Gastroenterology 2008; 134: 975-980.
Go to original source...
Go to PubMed...
- Al Mamari S, Djordjevic J, Halliday JS, et al. Improvement of serum alkaline phosphatase to < 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013; 58: 329-334.
Go to original source...
Go to PubMed...
- Hilscher M, Enders FB, Carey EJ, et al. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. Ann Hepatol 2016; 15: 246-253.
Go to PubMed...
- Lindstrom L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013; 11: 841-846.
Go to original source...
Go to PubMed...
- Rupp C, Rossler A, Halibasic E et, al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther 2014; 40: 1292-1301.
Go to original source...
Go to PubMed...
- Kim WR, Poterucha JJ, Wiesner RH, et al. The relative role of the Child‑Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999; 29: 1643-1648.
Go to original source...
Go to PubMed...
- Lindor KD, Kowdley KV, Luketic VA, et al. High‑dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (Baltimore, Md) 2009; 50: 808-814.
Go to original source...
Go to PubMed...
- Imam MH, Sinakos E, Gossard AA, et al. High‑dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34: 1185-1192.
Go to original source...
Go to PubMed...
- Roger Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of Primary Sclerosing Golangitis. Hepatology 2010; 51: 660-678.
Go to original source...
Go to PubMed...
- Othman MO, Dunkelberg J, Roy PK. Ursodeoxycholic acid in primary sclerosing cholangitis: a meta‑analysis and systematic review. Arab J Gastroenterol 2012; 13: 103-110.
Go to original source...
Go to PubMed...
- Triantos CK, Koukias NM, Nikolopoulou VN, et al. Meta‑analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34: 901-910.
Go to original source...
Go to PubMed...
- Stanich PP, Björnsson E, Gossard AA, et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Digestive and liver disease 2011; 43: 309-313.
Go to original source...
Go to PubMed...
- Wunsch E, Trottier J, Milkiewicz M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology 2014; 60: 931-940.
Go to original source...
Go to PubMed...
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. Journal of Hepatology 2009; 51: 237-267.
Go to original source...
Go to PubMed...
- Gluck M, Cantone NR, Brandabur JJ, et al. A twenty‑year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol 2008; 42: 1032-1039.
Go to original source...
Go to PubMed...
- Hazel SJ, Wolfhagen EH, van Buuren HR, et al. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group Endoscopy 2000; 32: 779-782.
Go to original source...
Go to PubMed...
- Ponsioen CY, Arnelo U, Bergquist A, et al. No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. Gastroenterology 2018; pii: S0016-5085(18)34567-0.
- Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98.
Go to original source...
Go to PubMed...
- Hofmann AF, Zakko SF, Lira M, et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 2005; 42: 1391-1398.
Go to original source...
Go to PubMed...
- Fickert P, Pollheimer MJ, Silbert D, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013; 58: 1201-1208.
Go to original source...
Go to PubMed...
- Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017; 67: 549-558.
Go to original source...
Go to PubMed...
- Li Y, Tang R, Leung PSC, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev 2017; 16: 885-896.
Go to original source...
Go to PubMed...
- Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients with primarysclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009; 104: 83-88.
Go to original source...
Go to PubMed...
- Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis‑a pilot study. Aliment Pharmacol Ther 2013; 37: 604-612.
Go to original source...
Go to PubMed...
- Färkkilä M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebocontrolled trial. Hepatology 2004; 40: 1379-1386.
Go to original source...
Go to PubMed...
- Davies YK, Cox KM, Abdullah BA, et al. Long‑term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47: 61-67.
Go to original source...
Go to PubMed...
- Allegretti J, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation improves microbiome diversity and liver enzyme profile in primary sclerosing cholangitis. In: World Congr. Gastroenterol. ACG2017. Orlando 2017, P1425.
Go to original source...
- Kowdley KV, Bowlus CL, Levy C, et al. The AESOP Trial: A Randomized, Double Blind, Placebo‑Controlled, Phase 2 Study of Obeticholic Acid in Patients with Primary Sclerosing Cholangitis. Hepatology 2017; 66: 1254 A-1255A.
- Mizuno S, Hirano K, Isayama H, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. Journal of hepato‑biliary‑pancreatic sciences 2015; 22: 766-770.
Go to original source...
Go to PubMed...
- Dejman A, Clark V, Martin P, et al. Tu1002 fenofibrate improves alkaline phosphatase in primary sclerosing cholangitis. Gastroenterology 2013; 144: S-1028.
Go to original source...
- Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327.
Go to original source...
Go to PubMed...
- Claessen MMH, Vleggaar FP, Tytgat KMAJ, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-164.
Go to original source...
Go to PubMed...
- de Valle MB, Björnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population based cohort. Liver Int 2012; 32: 441-448.
Go to original source...
Go to PubMed...
- Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002; 37: 1205-1211.
Go to original source...
Go to PubMed...
- Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-526.
Go to original source...
Go to PubMed...
- Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017; 152: 1975-1984.
Go to original source...
Go to PubMed...
- Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005; 50: 1734-1740.
Go to original source...
Go to PubMed...
- Sinakos E, Saenger AK, Keach J, et al. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 434-439.
Go to original source...
Go to PubMed...
- Horsley‑Silva JL, Rodriguez EA, Franco DL, et al. An update on cancer risk and surveillance in primary sclerosing cholangitis. Liver Int 2017; 37: 1103-1109.
Go to original source...
Go to PubMed...
- Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008; 48: 598-605.
Go to original source...
Go to PubMed...
- Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-164.
Go to original source...
Go to PubMed...
- Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-1408.
Go to original source...
Go to PubMed...
- Claessen MM, Lutgens MW, van Buuren HR, et al. More right‑sided IBD‑associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009; 15: 1331-1336.
Go to original source...
Go to PubMed...
- Sedki M, Levy C. Update in the Care and Management of Patients with Primary Sclerosing Cholangitis. Curr Gastroenterol Rep 2018; 20: 29.
Go to original source...
Go to PubMed...
- Matsuzaki Y, Tanaka N, Osuga T, et al. Improvement of biliary enzyme levels and itching as a result of long‑term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 1990; 85: 15-23.
- Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012; 16: 331-346.
Go to original source...
Go to PubMed...
- Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile acid binding agents, opioid antagonists or rifampin in the treatment of cholestasis‑associated pruritus. Am J Gastroenterol 2007; 102: 1528-1536.
Go to original source...
Go to PubMed...
- Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta‑analysis of prospective randomized‑controlled trials. Liver Int 2006; 26: 943-948.
Go to original source...
Go to PubMed...
- Imam MH, Gossard AA, Sinakos E, et al. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol 2012; 27: 1150-1158.
Go to original source...
Go to PubMed...
- Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975; 82: 310-317.
Go to original source...
Go to PubMed...
- Gasser RW. Cholestasis and metabolic bone disease - a clinical review. Wien Med Wochenschr 2008; 158: 553-557.
Go to original source...
Go to PubMed...
- Wolfhagen FH, van Buuren HR, den Ouden JW, et al. Cyclical etidronate in the prevention of bone loss in corticosteroid‑treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997; 26: 325-330.
Go to original source...
Go to PubMed...
- Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo‑controlled trial. Hepatology 2005; 42: 762-771.
Go to original source...
Go to PubMed...
- Bodingbauer M, Wekerle T, Pakrah B, et al. Prophylactic bisphosphonates treatment prevents bone fractures after liver transplantation. Am J Transplant 2007; 7: 1763-1769.
Go to original source...
Go to PubMed...
- Misof BM, Bodingbauer M, Roschger P, et al. Short‑term effects of high dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation. Calcif Tissue Int 2008; 83: 167-175.
Go to original source...
Go to PubMed...